



NOVA

University of Newcastle Research Online

[nova.newcastle.edu.au](http://nova.newcastle.edu.au)

Mylona, Eugenia; Ebert, Martin; Kennedy, Angel; Joseph, David; Denham, James; Steigler, Allison; Supiot, Stephane; Acosta, Oscar; de Crevoisier, Renaud "Rectal and Urethro-Vesical Subregions for Toxicity Prediction After Prostate Cancer Radiation Therapy: Validation of Voxel-Based Models in an Independent Population." *International Journal of Radiation Oncology Biology Physics* Vol. 108, Issue 5, p. 1189-1195.

**Available from:** <http://dx.doi.org/10.1016/j.ijrobp.2020.07.019>

© 2020. This manuscript version is made available under the CC-BY-NC-ND 4.0 license  
<http://creativecommons.org/licenses/by-nc-nd/4.0/>

**Accessed from:** <http://hdl.handle.net/1959.13/1444359>

## ***Rectal and Urethro-vesical Subregions for Toxicity Prediction After Prostate Cancer***

### ***Radiotherapy: validation of voxel-based models in an independent population***

#### **ABSTRACT**

**Purpose/Objectives:** Recent voxel-based studies have shown that the dose to specific rectal and urethro-vesical subregions is predictive of toxicities, following prostate cancer IMRT. The objective of this study was to validate the discriminatory power of these subregions with respect to the whole organs, in a large independent population.

**Material/Methods:** The validation cohort consisted of 450 patients, from the XXX(BLIND) trial, treated with 3D-CRT at a total of 66-74 Gy. Previous voxel-based analyses identified an infero-anterior rectal subregion as predictive of rectal bleeding and five subregions in the urethra and the posterior and superior part of the bladder as predictive of urinary incontinence, dysuria, retention and hematuria. In the validation cohort, these subregions were segmented in each patient's anatomy. DVHs of the whole organs and the six subregions were compared bin-wise between patients with and without toxicities. The discriminatory power of DVHs for grade $\geq$ 2 toxicity endpoints was assessed using the area under the ROC curve (AUC).

**Results:** Subregion DVHs were significantly different between patients with and without toxicities for late rectal bleeding (V44-V74), acute urinary incontinence (V68-V72), late dysuria (V56-V68) and late retention (V14-V64). The dose to the rectal subregion and the whole rectum were equally predictive of rectal bleeding (V68;AUC=0.61). The doses to three out of the five urethro-vesical subregions were found to be more predictive than the dose to the whole bladder: in the urethra for acute incontinence (V71;AUC=0.69 versus V71;AUC=0.66), in the posterior part of the bladder for late dysuria (V65;AUC=0.66 vs V68;AUC=0.59) and late retention (V39;AUC=0.74 vs no significant AUC).

**Conclusion:** Three subregions located in the urethra and the bladder were successfully validated as more predictive of urinary toxicity than the whole bladder. Sparing in particular the posterior part of the bladder, corresponding to late urinary retention, should be prioritized in treatment planning.

## Introduction

Gastrointestinal (GI) and genitourinary (GU) toxicities following prostate cancer radiotherapy are the most common radiation-induced complications, with 5-year grade  $\geq 2$  rates ranging from 6 to 38% and from 10 to 46%, respectively (1–3). Traditionally, dose-volume histogram (DVH) parameters extracted from the whole organ-at-risk are used to analyze the dose-effect relationships. Recently, novel approaches, commonly referred as voxel-based methods, enabled the analysis of the entire 3D dose distribution at fine spatial scales, providing evidence of variable intra-organ radiosensitivity (4–7). Such approaches rely on deformable image registration to align patient anatomies and map dose distributions to a common space of reference, enabling voxel-by-voxel dosimetric comparisons between patients with/without toxicity (8).

Two studies, aiming at identifying organ subregions predictive of GI and GU toxicities, applied voxel-based analyses on a dataset of 254 patients with localized prostate cancer, treated with IMRT/IGRT at total dose 78/80Gy, from two prospective trials (9, 10). A subregion located in the inferior-anterior hemi-anorectum predictive of late rectal bleeding (5) and five urethro-vesical subregions predictive of grade  $\geq 1$  GU toxicities (6) were identified. However, the predictive value of these subregions was assessed in the same cohort used for model development (herein called “development” cohort). In order to translate these findings into clinical practice, the improvement in toxicity prediction when considering these subregions, compared to the whole organ, needs to be demonstrated in independent populations. In addition, the superiority of the subregions should be confirmed for more clinically relevant toxicity events (grade  $\geq 2$ ).

The objective of this study was, thus, to validate in a large independent population (herein called “validation” cohort), the predictive value of these rectal and urethro-vesical subregions for grade  $\geq 2$  GI and GU toxicity prediction.

## MATERIALS AND METHODS

### *VALIDATION COHORT CHARACTERISTICS*

The validation cohort comprises 450 patients from the prospective XXX(BLIND) trial, treated with 3DCRT at a total dose of 66, 70 or 74 Gy (2Gy/fraction) (11). This trial is registered with

number XXX(BLIND) in ClinicalTrials.gov. Patient and treatment characteristics are summarized in Table A1 (Supplementary material). The median follow-up was 72 months. Rectal and urinary toxicities were assessed using the LENT/SOMA and IPSS systems. Grade $\geq$ 2 toxicity rates were 23% for rectal bleeding and ranged from 2 to 16% for urinary toxicities.

The radiation treatment technique and organ dose constraints for the development and validation cohorts are described in Supplementary material (Appendix A). More details can also be found in previous publications (5, 6, 11–14).

Figure 1 shows the workflow of the study.

#### *DEFINITION OF RECTAL AND URINARY TOXICITY SUBREGIONS IN THE VALIDATION COHORT*

Concerning rectal toxicity, a voxel-wise analysis of the dose distributions in the rectum allowed the identification of a generic, geometrically-defined subregion, predictive of 3-year rectal bleeding (grade $\geq$ 1 and grade $\geq$ 2) (Figure 1A) (5). In the validation cohort, a dedicated software (XXX(BLIND)) was used to automatically segment this subregion in each individual's anatomy (Figure 1B).

Concerning urinary toxicity, a voxel-wise analysis of the dose distribution in the bladder and the urethra allowed the identification of five subregions predictive of acute retention and incontinence and late retention, incontinence, dysuria and hematuria (Figure A1) (6). In the validation cohort, the prostatic urethra was, first, segmented on planning CT images using a multi-atlas-based segmentation algorithm (15). Then, the five urethro-vesical subregions, defined in a template-patient, were non-rigidly registered to each individual's anatomy. Registration accuracy was assessed using the Dice score ( $0.88\pm 0.04$  for the prostate and  $0.92\pm 0.06$  for the bladder).

Figure 2A displays the six subregions identified in the development cohort.

#### *STATISTICAL ANALYSIS*

All the analyses were performed using the physical dose. DVHs were computed for the rectum, the bladder, the urethra and the six subregions. Wilcoxon test was performed bin-wise to compare patients with and without grade $\geq$ 2 toxicities. For each endpoint studied, patients with relevant baseline symptoms were excluded from the analysis (Supplementary material; Table A1). The discriminatory power of the DVHs was assessed in univariate analysis using logistic regression and the area under the ROC curve (AUC) for acute toxicities while Cox regression and the time-

dependent AUC (tAUC) (16) were used for late toxicities. Bootstrapping with 1000 replicates was performed to determine AUC, t-AUC, and 95% confidence intervals.

## RESULTS

Figure 3 displays organ and subregion DVHs for patients with and without toxicities. Considering the subregions, significant differences were found for late rectal bleeding (V44-V74), acute urinary incontinence (V68-V72), late dysuria (V56-V68) and late retention (V14-V64). Considering the whole organs, significant differences were found for late rectal bleeding (V63-V74), acute urinary incontinence (V67-V72) and late hematuria (V65-V70).

Table 1B shows the discriminatory power of the DVHs for the bladder, the rectum, the urethra and the six subregions. The DVHs of the whole rectum and the rectal subregion demonstrated equal discriminatory power (V68; tAUC=0.61[95%CI: 0.55-0.66]). The doses to three urethro-vesical subregions were predictive for grade $\geq$ 2 acute incontinence (V71; AUC=0.69 [95%CI:0.60-0.80]), late retention (V39; tAUC=0.74[95%CI:0.62-0.87]) and late dysuria (V65; tAUC=0.66[95%CI: 0.59-0.73]). The dose to the whole urethra was predictive only for grade $\geq$ 2 acute incontinence (V71; AUC=0.68 [95%CI:0.60-0.79]). The dose to the whole bladder was predictive for acute incontinence (V71; AUC=0.66 [95%CI:0.56-0.75]) and late dysuria (V68; tAUC=0.59 [95%CI:0.50-0.69]). Figure 4 shows the discriminatory ability of the DVHs (bin-wise) for the subregions and the whole organs.

Figure 2B displays the three subregions confirmed as more predictive than the whole organs in the validation cohort.

## DISCUSSION

Voxel-wise analysis is a novel approach allowing the identification of subregions in organs-at-risk potentially predictive of toxicity. External validation of previously developed voxel-based spatial models (5, 6) was performed, confirming that symptom-specific local dose-effect patterns exist in the urethra for acute urinary incontinence and in the bladder for late retention and dysuria.

By considering the dose to these subregions, instead of the whole bladder, the ability of the models to discriminate patients with and without grade $\geq 2$  toxicities was improved.

In practice, sparing all the three subregions in treatment planning, although promising for reducing multiple urinary side-effects, may not always be feasible. In this context, some structures can be considered as more important than others. Even if subregions have been validated for clinically relevant toxicity endpoints (grade  $\geq 2$ ), late symptoms, namely retention and dysuria, are expected to more severely affect a patient's quality of life because of their prolonged duration. Late retention, in particular, has higher prevalence in both populations and the corresponding predictive model exhibits superior discrimination performance. Thus, sparing the posterior part of the bladder (above the trigone) corresponding to late retention, should be prioritized in treatment planning. Apart from the bladder, current findings also indicate a dose-effect relationship in the entire urethral volume for acute urinary incontinence. Even so, reducing the dose to the urethra requires more advanced treatment techniques, such as urethra-sparing stereotactic body radiation therapy (US-SBRT) (17).

On the other hand, two bladder subregions previously identified as predictive for acute retention and late hematuria, as well as the subregion in the rectum associated with rectal bleeding, were not confirmed in the validation cohort as more predictive than the whole organ. Differences between population settings (Tables A1), including the treatment technique, toxicity rates and geographic/temporal aspects, raise questions about a potential "cohort-effect" when performing population-based analyses (18). The significant differences in bladder volume (see Table A1) due to the different bladder filling protocols applied in the two populations is noteworthy. In the validation cohort, toxicity rates were also higher (Table 1A). For instance, rates of grade $\geq 2$  rectal bleeding were four times higher than in the development cohort, possibly due to the use of 3DCRT (1). Overall, these differences may have implications on the generalizability of some subregions.

A limitation of this work is that the statistical DVH-based predictive models, obtained from the development cohort, could not be directly applied to the validation cohort as a part of the external validation process(19). This is due to the differences in the prescribed doses between the two populations. Moreover, the validation cohort was treated with 3D-CRT with prescribed doses  $\leq 74$  Gy, which is not representative of the current clinical practices, where higher and conformal doses are delivered to the tumor. Another weakness arises from the consideration of the planning dose distribution which may differ from the actual delivered dose due to intra- and inter-fraction

anatomical variations (20, 21). Finally, clinical and biological parameters were not tested in a multivariate setting.

In conclusion, the present study validates three bladder and urethra subregions as more predictive of urinary toxicity, than the whole bladder. These findings highlight the need to go beyond the whole organ-based dosimetric constraints, towards optimized, patient-tailored sub-organ constraints. Clinical trials, however, are needed to demonstrate that these optimized planning strategies are able to significantly reduce urinary toxicity in the case of prostate cancer radiotherapy.

## REFERENCES

1. Wortel RC, Incrocci L, Pos FJ, *et al.* Late Side Effects After Image Guided Intensity Modulated Radiation Therapy Compared to 3D-Conformal Radiation Therapy for Prostate Cancer: Results From 2 Prospective Cohorts. *Int. J. Radiat. Oncol. Biol. Phys.* 2016;95:680–689.
2. Jolnerovski M, Salleron J, Beckendorf V, *et al.* Intensity-modulated radiation therapy from 70Gy to 80Gy in prostate cancer: six- year outcomes and predictors of late toxicity. *Radiat. Oncol.* 2017;12:99.
3. Zelefsky MJ, Cowen D, Fuks Z, *et al.* Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. *Cancer.* 1999;85:2460–2468.
4. Palma G, Monti S, D'Avino V, *et al.* A Voxel-Based Approach to Explore Local Dose Differences Associated With Radiation-Induced Lung Damage. *Int. J. Radiat. Oncol. Biol. Phys.* 2016;96:127–133.
5. Dréan G, Acosta O, Ospina JD, *et al.* Identification of a rectal subregion highly predictive of rectal bleeding in prostate cancer IMRT. *Radiother. Oncol.* 2016;119:388–97.
6. Mylona E, Acosta O, Lizee T, *et al.* Voxel-Based Analysis for Identification of Urethrovesical Subregions Predicting Urinary Toxicity After Prostate Cancer Radiation Therapy. *Int. J. Radiat. Oncol. Biol. Phys.* 2019;104:343–354.
7. McWilliam A, Kennedy J, Hodgson C, *et al.* Radiation dose to heart base linked with poorer survival in lung cancer patients. *Eur. J. Cancer.* 2017;85:106–113.
8. Acosta O, Drean G, Ospina JD, *et al.* Voxel-based population analysis for correlating local dose and rectal toxicity in prostate cancer radiotherapy. *Phys. Med. Biol.* 2013;58:2581–95.
9. de Crevoisier R, Bayar MA, Pommier P, *et al.* Daily Versus Weekly Prostate Cancer Image Guided Radiation Therapy: Phase 3 Multicenter Randomized Trial. *Int. J. Radiat. Oncol. Biol. Phys.* 2018;102:1420–1429.
10. Catton CN, Lukka H, Gu C-S, *et al.* Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. *J. Clin. Oncol.* 2017;35:1884–1890.
11. Denham JW, Wilcox C, Lamb DS, *et al.* Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer. *Radiother. Oncol.* 2012;105:184–192.
12. Yahya N, Ebert MA, Bulsara M, *et al.* Dosimetry, clinical factors and medication intake influencing urinary symptoms after prostate radiotherapy: An analysis of data from the RADAR prostate radiotherapy trial. *Radiother. Oncol.* 2015;116:112–118.
13. Ebert MA, Foo K, Haworth A, *et al.* Gastrointestinal dose-histogram effects in the context of dose-volume-constrained prostate radiation therapy: Analysis of data from the radar prostate radiation therapy trial. *Int. J. Radiat. Oncol. Biol. Phys.* 2015.
14. Haworth A, Kearvell R, Greer PB, *et al.* Assuring high quality treatment delivery in clinical

- trials - Results from the Trans-Tasman Radiation Oncology Group (TROG) study 03.04 “RADAR” set-up accuracy study. *Radiother. Oncol.* 2009;90:299–306.
15. Acosta O, Mylona E, Le Dain M, *et al.* Multi-atlas-based segmentation of prostatic urethra from planning CT imaging to quantify dose distribution in prostate cancer radiotherapy. *Radiother. Oncol.* 2017;125:492–499.
  16. Chambless LE, Diao G. Estimation of time-dependent area under the ROC curve for long-term risk prediction. *Stat. Med.* 2006;25:3474–3486.
  17. Sato M, Hirose K, Hatayama Y, *et al.* The Potential of the Urethra-Sparing Intensity Modulated Radiation Therapy for Localized Prostate Cancer for Preventing Genitourinary Toxicity: An Interim Analysis. *Int. J. Radiat. Oncol. Biol. Phys.* 2018;102:e140.
  18. Mylona E, Cicchetti A, Rancati T, *et al.* Local dose analysis to predict acute and late urinary toxicities after prostate cancer radiotherapy: Assessment of cohort and method effects. *Radiother. Oncol.* 2020;147:40–49.
  19. Moons KGM, Altman DG, Reitsma JB, *et al.* Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): Explanation and elaboration. *Ann. Intern. Med.* 2015;162:W1–W73.
  20. Nassef M, Simon A, Cazoulat G, *et al.* Quantification of dose uncertainties in cumulated dose estimation compared to planned dose in prostate IMRT. *Radiother. Oncol.* 2016;119:129–136.
  21. Fuchs F, Habl G, Devečka M, *et al.* Interfraction variation and dosimetric changes during image-guided radiation therapy in prostate cancer patients. *Radiat. Oncol. J.* 2019;37:127.

Symptom		A. Toxicity rates		B. Discriminatory power of the DVH (validation cohort)				
		Development cohort	Validation cohort	Anatomical region	Predictor (DVH bin)†	p value	OR/HR (95% CI)	AUC/tAUC
<b>Rectal toxicity</b>								
Rectal bleeding (at 3-years)		6% (3-9%)	23% (17-29%)	Whole rectum	V68	0.003**	1.04 (1.01-1.07)	0.61 (0.55-0.66)
				Subregion	V68	0.002**	1.02 (1-1.03)	0.61 (0.55-0.66)
<b>Urinary toxicity</b>								
Acute	Retention <sup>§</sup>	19 %	24%	Whole bladder	V56	0.601	1.01(0.99-1.02)	0.51 (0.38-0.59)
				Urethra	V74	0.451	1 (0.99-1.01)	0.52 (0.46-0.58)
				Subregion	V57	0.128	0.98 (0.95-1.01)	0.53 (0.49-0.61)
	Incontinence	0 %	7%	Whole bladder	V71	0.004**	1.05 (1.01-1.08)	0.66 (0.56-0.75)
				Urethra	V71	0.011*	1.02 (1.01-1.04)	0.68 (0.60-0.79)
				Subregion	V71	0.010*	1.03 (1.01-1.05)	0.69 (0.60-0.80)
Late (5 years)	Dysuria	1% (0-2%)	8% (5-11%)	Whole bladder	V68	0.037*	1.03 (1-1.06)	0.59 (0.50-0.69)
				Urethra	V70	0.137	1.05 (0.96-1.11)	0.54 (0.45-0.63)
				Subregion	V65	0.001**	1.02 (1-1.03)	0.66 (0.59-0.73)
	Retention <sup>§</sup>	10% (5-15%)	16% (9-22%)	Whole bladder	V37	0.054	1.02 (0.99-1.04)	0.59 (0.49-0.70)
				Urethra	V67	0.120	1.04 (0.99-1.08)	0.55 (0.50-0.60)
				Subregion	V39	0.009**	1.02 (1-1.03)	0.74 (0.62-0.87)
	Hematuria (grade $\geq$ 1)	2% (0-4%)	2% (0-4%)	Whole bladder	V70	0.094	1.02 (0.99-1.05)	0.56 (0.48-0.64)
				Urethra	V71	0.045*	1.01(1-1.02)	0.56 (0.5-0.63)
				Subregion	V48	0.261	0.97(0.93-1.01)	0.54 (0.49-0.58)


OR: Odds ratios; HR: Hazard ratio; CI: Confidence interval; AUC: Area under the ROC curve; tAUC: time-dependent area under the ROC curve; †DVH bin with the most significant AUC/tAUC (lowest p-value); § Urinary retention grade  $\geq$ 2 was defined in the validation cohort as IPSS-O  $\geq$ 11, where IPSS-O is the sum of the scores for the questions expressing an obstructive urinary effect (Questions 1, 3, 5 and 6). \* p-value  $\leq$ 0.05; \*\* p-value  $\leq$ 0.01.

**Table 1. Grade  $\geq$  2 toxicity rates in the development and validation cohorts (A) and toxicity discriminatory power of the whole organs' and subregions' DVHs (B)**

(A) Late toxicity rates and 95% confidence intervals were computed using the Kaplan-Meier method. (B) Logistic and Cox regression were used to compute the discriminatory power of DVHs for acute and late toxicities, respectively. Analysis was performed for grade $\geq$ 2 toxicities with the exception of hematuria for which the analysis was performed only for grade $\geq$ 1, due to the low number of grade $\geq$ 2 events.

## A. Development cohort (previous studies)

Voxel-wise analysis and subregion identification



## B. Validation cohort (present study)

subregion identification and evaluation of discriminatory power






Figure 1. Study workflow

(A) Rectal and urethro-vesical subregions predictive of GI and GU toxicities, were identified in previous studies using voxel-based methods (5, 6). (B) In the present study, these subregions were segmented in a validation cohort and their ability to discriminate patients with/without grade $\geq 2$  toxicities was evaluated.




**Figure 2. Subregions identified as predictive of GI and GU toxicities in the development cohort (A) and subregions confirmed as predictive in the validation cohort (B)**

Three out of six subregions were confirmed as more predictive than the whole organ. All the subregions in (A) were identified for grade  $\geq 1$  toxicity endpoints. The subregions shown in (B) were confirmed for grade  $\geq 2$  toxicity endpoints.



**Figure 3. Dose–volume histograms of the subregions and the whole organs for patients with and without toxicities in the validation cohort**

Red and green curves represent the average DVHs of the patient with/without toxicity symptoms (grade  $\geq 2$  toxicity), respectively. Continuous lines represent the subregions and dash lines the whole organ. The shadowed regions indicate dose bins with significant differences between patients with/without toxicity (Wilcoxon test;  $p \leq 0.05$ ). DVHs were computed for grade  $\geq 2$  toxicity with the exception of hematuria for which the analysis was performed only for grade  $\geq 1$ , due to the low number of grade  $\geq 2$  events.



**Figure 4. Bin-wise grade  $\geq 2$  discriminatory power of the DVHs for the subregions and the whole organs**

Logistic regression was used to compute the discriminatory power of the DVH for acute toxicity (incontinence) and Cox regression for late toxicity (rectal bleeding, dysuria and hematuria). X-axis represents the dose level ( $x$ ) corresponding to the volume ( $V_x$ ) of the DVH. Continuous and dashed lines represent the p-values  $\leq 0.05$  and p-values  $> 0.05$ , respectively. Blue and orange lines represent the discriminatory power of the DVH in the subregions and the whole organs (bladder/rectum), respectively.